Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Current Deferred Revenue (2016 - 2025)

STRATA Skin Sciences (SSKN) has disclosed Current Deferred Revenue for 14 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue changed 0.31% to $2.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Dec 2025, changed 0.31% year-over-year, with the annual reading at $2.2 million for FY2025, 0.31% changed from the prior year.
  • Current Deferred Revenue hit $2.2 million in Q4 2025 for STRATA Skin Sciences, down from $2.6 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $3.8 million in Q3 2021 to a low of $2.1 million in Q4 2023.
  • Historically, Current Deferred Revenue has averaged $2.6 million across 5 years, with a median of $2.4 million in 2023.
  • Biggest five-year swings in Current Deferred Revenue: soared 132.84% in 2021 and later fell 25.12% in 2023.
  • Year by year, Current Deferred Revenue stood at $3.3 million in 2021, then fell by 15.43% to $2.8 million in 2022, then dropped by 23.69% to $2.1 million in 2023, then rose by 5.71% to $2.2 million in 2024, then rose by 0.31% to $2.2 million in 2025.
  • Business Quant data shows Current Deferred Revenue for SSKN at $2.2 million in Q4 2025, $2.6 million in Q3 2025, and $2.4 million in Q2 2025.